Regenerative Medical Technology Group Inc. (RMTG)
Q4-CY2025Q3-CY2025Q2-CY2025Q1-CY2025Q4-CY2024Q3-CY2024Q2-CY2024Q1-CY2024Q4-CY2023Q3-CY2023Q2-CY2023Q1-CY2023Q4-CY2022Q3-CY2022Q2-CY2022Q1-CY2022Q4-CY2021Q3-CY2021Q2-CY2021Q1-CY2021Q4-CY2020Q3-CY2020Q2-CY2020Q1-CY2020Q4-CY2019Q3-CY2019Q2-CY2019Q1-CY2019Q4-CY2018Q3-CY2018Q2-CY2018Q1-CY2018Q4-CY2017Q3-CY2017Q2-CY2017Q1-CY2017Q4-CY2016Q3-CY2016Q2-CY2016Q1-CY2016Q4-CY2015Q3-CY2015Q2-CY2015Q1-CY2015Q4-CY2014Q3-CY2014Q2-CY2014Q1-CY2014Q4-CY2013
Balance Sheet Date2025-Sep-302025-Jun-302025-Mar-312024-Dec-312024-Sep-302024-Jun-302024-Mar-312023-Dec-312021-Mar-312020-Dec-312020-Sep-302020-Jun-302020-Mar-312019-Dec-312019-Sep-302019-Jun-302019-Mar-312018-Dec-31
Fiscal PeriodQ3-FY2025Q2-FY2025Q1-FY2025Q4-FY2024Q3-FY2024Q2-FY2024Q1-FY2024Q4-FY2023Q1-FY2021Q4-FY2020Q3-FY2020Q2-FY2020Q1-FY2020Q4-FY2019Q3-FY2019Q2-FY2019Q1-FY2019Q4-FY2018
Operating Cash Flow(203,731$)(598,093$)57,109$379,393$272,942$90,398$107,966$(29,399$)10,138$(406,713$)6,775$(154,860$)(96,939$)(92,096$)(69,028$)(64,682$)(48,450$)(134,679$)(86,570$)(92,626$)(73,869$)(68,209$)(67,625$)(34,937$)
Investing Cash Flow(224,829$)(50,000$)(53,608$)(52,657$)(59,154$)(284,002$)(91,387$)(4,721$)(5,486$)0$(125,000$)0$
Purchases of Property and Equipment224,829$50,000$53,608$52,657$59,154$284,002$91,387$4,721$5,486$0$
Financing Cash Flow0$(300,000$)0$0$(9,850$)900,000$80,000$265,000$119,300$52,600$71,801$94,559$126,140$62,370$74,392$76,750$91,914$28,668$
End Cash Position1,185,695$1,614,254$1,222,929$1,165,820$836,427$617,093$579,352$530,540$1,143,941$1,225,190$1,636,624$1,645,185$2,978,525$787,674$42,534$59,473$11,569$11,379$23,379$28$40,148$578$30,834$30,311$25,770$7,750$
Exchange Rate Effect
Dividends Paid
Unlevered Free Cash Flow(428,560$)(598,093$)57,109$329,393$219,334$37,741$48,812$(313,401$)(81,249$)(411,434$)1,289$(154,860$)(96,939$)(92,096$)(69,028$)(64,682$)(48,450$)(134,679$)(86,570$)(92,626$)(73,869$)(68,209$)(67,625$)(34,937$)